Treatment for B-cell lymphoma that has come back or not responded
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new injectable treatment (called JY231) for people whose B-cell lymphoma has come back or did not respond to standard treatments. The treatment targets a specific marker on cancer cells (CD19) and may help when other options have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have B-cell lymphoma that has come back or did not respond to at least two previous treatments (or a stem cell transplant).
- Your cancer cells test positive for a marker called CD19.
- You have at least one tumor that can be seen on a scan and is active (shows up on a PET scan).
- You are generally well enough to be up and about (ECOG score 0 or 1).
- Your heart, lungs, liver, and kidneys are working well enough, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
This trial tests a new therapy called JY231 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if this therapy can help control the leukemia and improve outcomes.
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
Hear when a new B-Non Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.